Bio-Rad Laboratories, Inc.
BIO
$251.48
$0.470.19%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 667.48M | 649.73M | 638.48M | 610.82M | 681.12M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 667.48M | 649.73M | 638.48M | 610.82M | 681.12M |
| Cost of Revenue | 325.56M | 293.83M | 282.76M | 284.35M | 314.81M |
| Gross Profit | 341.91M | 355.90M | 355.72M | 326.47M | 366.32M |
| SG&A Expenses | 204.36M | 200.34M | 195.72M | 210.48M | 207.52M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 609.55M | 585.16M | 537.98M | 559.01M | 586.20M |
| Operating Income | 57.93M | 64.57M | 100.50M | 51.81M | 94.92M |
| Income Before Tax | -908.92M | 861.62M | -2.79B | 491.08M | 428.40M |
| Income Tax Expenses | -193.12M | 208.45M | -620.80M | 107.16M | 78.66M |
| Earnings from Continuing Operations | -715.80M | 653.17M | -2.17B | 383.92M | 349.73M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -715.80M | 653.17M | -2.17B | 383.92M | 349.73M |
| EBIT | 57.93M | 64.57M | 100.50M | 51.81M | 94.92M |
| EBITDA | 97.13M | 103.47M | 136.90M | 88.91M | 132.12M |
| EPS Basic | -25.57 | 23.37 | -76.26 | 13.46 | 12.15 |
| Normalized Basic EPS | 1.40 | 1.49 | 2.37 | 1.67 | 2.21 |
| EPS Diluted | -25.57 | 23.34 | -76.26 | 13.45 | 12.13 |
| Normalized Diluted EPS | 1.40 | 1.49 | 2.37 | 1.67 | 2.21 |
| Average Basic Shares Outstanding | 28.00M | 27.95M | 28.40M | 28.52M | 28.79M |
| Average Diluted Shares Outstanding | 28.00M | 27.99M | 28.40M | 28.54M | 28.82M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
